<--- Back to Details
First PageDocument Content
Interventional cardiology / Drug delivery / Medical equipment / Drug-eluting stent / Paclitaxel
Date: 2016-07-06 08:58:35
Interventional cardiology
Drug delivery
Medical equipment
Drug-eluting stent
Paclitaxel

Mathematical challenges in controlled drug delivery J OSÉ AUGUSTO F ERREIRA CMUC , DEPARTMENT OF MATHEMATICS - UNIVERSITY OF COIMBRA

Add to Reading List

Source URL: www.ciencia2016.pt

Download Document from Source Website

File Size: 810,34 KB

Share Document on Facebook

Similar Documents

CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Model-Based Meta-Analysis for Quantifying Paclitaxel Dose Response in Cancer Patients Authors D Lu, A Joshi, H Li, N Zhang, MM Ren, Y Gao, R Wada and JY Jin

CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Model-Based Meta-Analysis for Quantifying Paclitaxel Dose Response in Cancer Patients Authors D Lu, A Joshi, H Li, N Zhang, MM Ren, Y Gao, R Wada and JY Jin

DocID: 1uOYW - View Document

2013 年 Ⅰ.原著論文 1) Yamada K, Tanabe H, Imai M, Jobo T, Kudo K, Fujiwara H, Nagata C, Furuya K, Suzuki M, Ochiai K, Tanaka T, Yasuda M. Feasibility study of paclitaxel plus

2013 年 Ⅰ.原著論文 1) Yamada K, Tanabe H, Imai M, Jobo T, Kudo K, Fujiwara H, Nagata C, Furuya K, Suzuki M, Ochiai K, Tanaka T, Yasuda M. Feasibility study of paclitaxel plus

DocID: 1uc4P - View Document

Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu

Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu

DocID: 1t7ew - View Document

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1

DocID: 1t6TW - View Document

Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

DocID: 1t3Wy - View Document